The story
In 2016 the United Kingdom produced 95 tonnes of legal cannabis for medical and scientific use, making it the world’s largest producer and exporter even though ordinary British patients had no general route to herbal medical cannabis.
The UN figures
The number came from government data compiled by the International Narcotics Control Board and reported in March 2018. Legal UK production rose from 42 tonnes in 2015 to 95 tonnes in 2016, more than doubling in a year.
“Production” in the international reporting system has a specific technical meaning: separating cannabis or cannabis resin from the plants. The figure concerned licensed activity, not estimates of the illegal domestic market.
A licensed medicine
Much of the crop was connected with Sativex, a standardised whole-plant cannabis extract made by GW Pharmaceuticals and administered as a spray. HortiDaily described it as the United Kingdom’s one licensed cannabis-based medicine at the time and said it was available on prescription through the NHS only in Wales.
That narrow product route helps explain the apparent contradiction. A company could hold licences to cultivate and process cannabis for a medicine and export market while cannabis itself remained prohibited for recreational use and unavailable to most patients as flower.
Production without broad access
The government position reported in 2018 was that cannabis had no therapeutic value. Critics contrasted that statement with the licences supporting the world’s largest legal production and export industry.
The policy changed later that year. From 1 November 2018, specialist doctors could prescribe cannabis-based medicines. Access nevertheless remained much narrower than the production number might suggest.
What the number does not show
Ninety-five tonnes did not mean that British consumers could buy cannabis, grow it or receive it routinely from the health service. It measured a licensed pharmaceutical supply chain dominated by a specific producer and product.
Why the index did not move
The 2016 production record revealed the scale of an existing licensed exception; it did not itself change the law or patient eligibility. The United Kingdom’s six scores therefore stay unchanged at this contextual event. The access score moves only at reforms that alter lawful availability.[1][2]
Listed for context. No score change is recorded for United Kingdom here.
References
Checked. The date and the event were compared with a source that was read.